These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 35858016)

  • 1. Highlights of clinical and laboratory parameters among severe COVID-19 patients treated with tocilizumab: a retrospective observational study.
    Şener MU; Çiçek T; Öztürk A
    Sao Paulo Med J; 2022; 140(5):627-635. PubMed ID: 35858016
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tocilizumab demonstrates superiority in decreasing C-reactive protein levels in hospitalized COVID-19 patients, compared to standard care treatment alone.
    Calderón-Ochoa C; Plamenov-Donchev N; Hernández-Quiñones F; Mendoza-López O; Hinojos-Gallardo LC; Longino-Gómez AJ; Hernádez-Saldaña R; Duque-Rodríguez J; Ishida-Gutiérrez MC
    Microbiol Spectr; 2024 Jun; 12(6):e0249823. PubMed ID: 38687065
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Efficacy of Tocilizumab in COVID-19: Single-Center Experience.
    Kaya S; Kavak S
    Biomed Res Int; 2021; 2021():1934685. PubMed ID: 34977235
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Tocilizumab in patients with severe COVID-19: A single-center observational analysis.
    Knorr JP; Colomy V; Mauriello CM; Ha S
    J Med Virol; 2020 Nov; 92(11):2813-2820. PubMed ID: 32628003
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Tocilizumab Treatment for Cytokine Release Syndrome in Hospitalized Patients With Coronavirus Disease 2019: Survival and Clinical Outcomes.
    Price CC; Altice FL; Shyr Y; Koff A; Pischel L; Goshua G; Azar MM; Mcmanus D; Chen SC; Gleeson SE; Britto CJ; Azmy V; Kaman K; Gaston DC; Davis M; Burrello T; Harris Z; Villanueva MS; Aoun-Barakat L; Kang I; Seropian S; Chupp G; Bucala R; Kaminski N; Lee AI; LoRusso PM; Topal JE; Dela Cruz C; Malinis M
    Chest; 2020 Oct; 158(4):1397-1408. PubMed ID: 32553536
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytokine Profiles Before and After Immune Modulation in Hospitalized Patients with COVID-19.
    Azmy V; Kaman K; Tang D; Zhao H; Dela Cruz C; Topal JE; Malinis M; Price CC
    J Clin Immunol; 2021 May; 41(4):738-747. PubMed ID: 33459964
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical characteristics and predictors of survival in adults with coronavirus disease 2019 receiving tocilizumab.
    Morrison AR; Johnson JM; Griebe KM; Jones MC; Stine JJ; Hencken LN; To L; Bianchini ML; Vahia AT; Swiderek J; Ramesh MS; Peters MA; Smith ZR
    J Autoimmun; 2020 Nov; 114():102512. PubMed ID: 32646770
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Tocilizumab for the treatment of adult patients with severe COVID-19 pneumonia: A single-center cohort study.
    Fernández-Ruiz M; López-Medrano F; Pérez-Jacoiste Asín MA; Maestro de la Calle G; Bueno H; Caro-Teller JM; Catalán M; de la Calle C; García-García R; Gómez C; Laguna-Goya R; Lizasoáin M; Martínez-López J; Origüen J; Pablos JL; Ripoll M; San Juan R; Trujillo H; Lumbreras C; Aguado JM
    J Med Virol; 2021 Feb; 93(2):831-842. PubMed ID: 32672860
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes in COVID-19 patients treated with tocilizumab: An individual patient data systematic review.
    Antwi-Amoabeng D; Kanji Z; Ford B; Beutler BD; Riddle MS; Siddiqui F
    J Med Virol; 2020 Nov; 92(11):2516-2522. PubMed ID: 32436994
    [TBL] [Abstract][Full Text] [Related]  

  • 10. IL-6 serum levels predict severity and response to tocilizumab in COVID-19: An observational study.
    Galván-Román JM; Rodríguez-García SC; Roy-Vallejo E; Marcos-Jiménez A; Sánchez-Alonso S; Fernández-Díaz C; Alcaraz-Serna A; Mateu-Albero T; Rodríguez-Cortes P; Sánchez-Cerrillo I; Esparcia L; Martínez-Fleta P; López-Sanz C; Gabrie L; Del Campo Guerola L; Suárez-Fernández C; Ancochea J; Canabal A; Albert P; Rodríguez-Serrano DA; Aguilar JM; Del Arco C; de Los Santos I; García-Fraile L; de la Cámara R; Serra JM; Ramírez E; Alonso T; Landete P; Soriano JB; Martín-Gayo E; Fraile Torres A; Zurita Cruz ND; García-Vicuña R; Cardeñoso L; Sánchez-Madrid F; Alfranca A; Muñoz-Calleja C; González-Álvaro I;
    J Allergy Clin Immunol; 2021 Jan; 147(1):72-80.e8. PubMed ID: 33010257
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Tocilizumab challenge: A series of cytokine storm therapy experiences in hospitalized COVID-19 pneumonia patients.
    Borku Uysal B; Ikitimur H; Yavuzer S; Ikitimur B; Uysal H; Islamoglu MS; Ozcan E; Aktepe E; Yavuzer H; Cengiz M
    J Med Virol; 2020 Nov; 92(11):2648-2656. PubMed ID: 32484930
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effect of anti-interleukin drugs in patients with COVID-19 and signs of cytokine release syndrome (COV-AID): a factorial, randomised, controlled trial.
    Declercq J; Van Damme KFA; De Leeuw E; Maes B; Bosteels C; Tavernier SJ; De Buyser S; Colman R; Hites M; Verschelden G; Fivez T; Moerman F; Demedts IK; Dauby N; De Schryver N; Govaerts E; Vandecasteele SJ; Van Laethem J; Anguille S; van der Hilst J; Misset B; Slabbynck H; Wittebole X; Liénart F; Legrand C; Buyse M; Stevens D; Bauters F; Seys LJM; Aegerter H; Smole U; Bosteels V; Hoste L; Naesens L; Haerynck F; Vandekerckhove L; Depuydt P; van Braeckel E; Rottey S; Peene I; Van Der Straeten C; Hulstaert F; Lambrecht BN
    Lancet Respir Med; 2021 Dec; 9(12):1427-1438. PubMed ID: 34756178
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effectiveness of anakinra for tocilizumab-refractory severe COVID-19: A single-centre retrospective comparative study.
    de la Calle C; López-Medrano F; Pablos JL; Lora-Tamayo J; Maestro-de la Calle G; Sánchez-Fernández M; Fernández-Ruiz M; Pérez-Jacoiste Asín MA; Caro-Teller JM; García-García R; Catalán M; Martínez-López J; Sevillano Á; Origüen J; Ripoll M; San Juan R; Lalueza A; de Miguel B; Carretero O; Aguilar F; Gómez C; Paz-Artal E; Bueno H; Lumbreras C; Aguado JM
    Int J Infect Dis; 2021 Apr; 105():319-325. PubMed ID: 33592340
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of Tocilizumab Therapy in Different Subtypes of COVID-19 Cytokine Storm Syndrome.
    Oliynyk O; Barg W; Slifirczyk A; Oliynyk Y; Gurianov V; Rorat M
    Viruses; 2021 Jun; 13(6):. PubMed ID: 34205217
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inflammation characteristics and anti-inflammation treatment with tocilizumab of severe/critical COVID-19 patients: A retrospective cohort study.
    Hu Q; Xu Y; Xiang Y; Wang B; Yuan Z; Shan Y; Zhang W; Wu N; Xia T; Li C; Xie W; Jia X; Yu Z; Bai L; Li Y
    Int J Biol Sci; 2021; 17(8):2124-2134. PubMed ID: 34131411
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assessment of Tocilizumab (Humanized Monoclonal Antibody) for Therapeutic Efficacy and Clinical Safety in Patients with Coronavirus Disease (COVID-19).
    Ullah S; Abid R; Haider S; Khuda F; Albadrani GM; Abdulhakim JA; Altyar AE; Abdel-Daim MM; Halimi SMA; Khalil AAK
    Medicina (Kaunas); 2022 Aug; 58(8):. PubMed ID: 36013543
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Prophylactic Tocilizumab Prior to Anti-CD19 CAR-T Cell Therapy for Non-Hodgkin Lymphoma.
    Caimi PF; Pacheco Sanchez G; Sharma A; Otegbeye F; Ahmed N; Rojas P; Patel S; Kleinsorge Block S; Schiavone J; Zamborsky K; Boughan K; Hillian A; Reese-Koc J; Maschan M; Dropulic B; Sekaly RP; de Lima M
    Front Immunol; 2021; 12():745320. PubMed ID: 34712233
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The association of interleukin-6 value, interleukin inhibitors, and outcomes of patients with COVID-19 in New York City.
    Maeda T; Obata R; Rizk DO D; Kuno T
    J Med Virol; 2021 Jan; 93(1):463-471. PubMed ID: 32720702
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Repurposed Tocilizumab in Patients with Severe COVID-19.
    Tian J; Zhang M; Jin M; Zhang F; Chu Q; Wang X; Chen C; Yue H; Zhang L; Du R; Zhao D; Zeng Z; Zhao Y; Liu K; Wang M; Hu K; Miao X; Zhang H
    J Immunol; 2021 Feb; 206(3):599-606. PubMed ID: 33298617
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The role of tocilizumab therapy in critically ill patients with severe acute respiratory syndrome coronavirus 2.
    Saffo Z; Guo W; Springer K; Maksimowicz-McKinnon K; Kak V; McKinnon JE; Bhargava P
    J Osteopath Med; 2021 Jul; 121(8):705-714. PubMed ID: 34237804
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.